

Title (en)
METHODS TO POTENTIATE INTRAVENOUS ESTRAMUSTINE PHOSPHATE

Title (de)
VERFAHREN ZUR POTENZIERUNG INTRAVENÖS ESTRAMUSTIN PHOSFAT

Title (fr)
PROCEDES DE POTENTIALISATION DE L'ESTRAMUSTINE PHOSPHATE INTRAVEINEUX

Publication
EP 1003521 A4 20030723 (EN)

Application
EP 99914884 A 19990326

Priority
• US 9904275 W 19990326
• US 7954298 P 19980327

Abstract (en)
[origin: WO9949869A1] Estramustine phosphate is an anti-mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administered at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.

IPC 1-7
A61K 31/56; **A61K 31/65**; **A61K 31/44**; **A61K 31/335**; **A61K 9/127**

IPC 8 full level
A61K 9/127 (2006.01); **A61K 9/08** (2006.01); **A61K 31/337** (2006.01); **A61K 31/437** (2006.01); **A61K 31/4468** (2006.01); **A61K 31/565** (2006.01); **A61K 31/704** (2006.01); **A61K 31/7042** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR)
A61K 9/08 (2013.01 - EP); **A61K 31/56** (2013.01 - KR); **A61P 35/00** (2018.01 - EP)

Citation (search report)
• [X] US 5728687 A 19980317 - BISSERY MARIE-CHRISTINE [FR]
• [X] US 4584136 A 19860422 - YOSHIDA MASARU [JP], et al
• [X] HUDES G R ET AL: "PACLITAXEL PLUS ESTRAMUSTINE IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER", SEMINARS IN ONCOLOGY, BETHESDA, MD, US, vol. 22, no. 5, SUPPL 12, October 1995 (1995-10-01), pages 41 - 45, XP001000716
• [PA] GARCIA A A ET AL: "PHASE I AND PHARMACOLOGIC STUDY OF ESTRAMUSTINE PHOSPHATE AND SHORTINFUSIONS OF PACLITAXEL IN WOMEN WITH SOLID TUMORS", JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 16, no. 9, September 1998 (1998-09-01), pages 2959 - 2963, XP001000703

Citation (examination)
• NAGEL ET AL: "Treatment of advanced carcinoma of the prostate with estramustine phosphate", BR.J.UROL., vol. 49, 1977, pages 73 - 79
• GUNNARSSON ET AL: "Pharmacokinetics of estramustine phosphate in prostatic cancer patients", EUR.J.PHARMACOL, vol. 26, 1984, pages 113 - 119
• See also references of WO 9949869A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9949869 A1 19991007; AU 3353399 A 19991018; AU 750010 B2 20020711; BR 9906425 A 20000711; CA 2295049 A1 19991007; CN 1273530 A 20001115; CN 1636598 A 20050713; EA 004647 B1 20040624; EA 199901081 A1 20001225; EP 1003521 A1 20000531; EP 1003521 A4 20030723; HU P0200547 A2 20020729; HU P0200547 A3 20030728; ID 24504 A 20000720; IL 133612 A0 20010430; JP 2001508810 A 20010703; KR 20010021656 A 20010315; NO 20002343 D0 20000504; NO 20002343 L 20000504; NZ 501987 A 20021025; PL 342969 A1 20010716; ZA 997821 B 20000801

DOCDB simple family (application)
US 9904275 W 19990326; AU 3353399 A 19990326; BR 9906425 A 19990326; CA 2295049 A 19990326; CN 200410086718 A 19990326; CN 99800823 A 19990326; EA 199901081 A 19990326; EP 99914884 A 19990326; HU P0200547 A 19990326; ID 20000105 A 19990326; IL 13361299 A 19990326; JP 54936999 A 19990326; KR 20007000214 A 20000110; NO 20002343 A 20000504; NZ 50198799 A 19990326; PL 34296999 A 19990326; ZA 997821 A 19991222